Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes—a Hellenic Cooperative Oncology Group (HeCOG) Trial
Authors:
Open Access
- 3 June 2020
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 123 (3) , 355-361
Abstract
Background: Cabazitaxel is a novel taxane that might be active in breast cancer resistant to first-generation taxanes. Methods: The purpose of the current multicentre phase II trial was to evaluate the activity and safety of cabazitaxel, as second-line treatment, in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) previously treated with taxanes. The primary endpoint was objective response rate (ORR). Results: Eighty-four patients were enrolled between October 2012 and November 2016. Taxane resistance to previous treatment was detected in 43 cases. The ORR was 22.6% in the intent-to-treat population, 23.3% in taxane-resistant and 20.5% in taxane-non-resistant cases. At a median follow-up of 39.6 months, the median progression-free survival and overall survival were 3.7 months (95% CI 2.2–4.4) and 15.2 months (95% CI 11.3–19.4), respectively. Regarding toxicity, grade 3–4 neutropenia was reported in 22.6% and febrile neutropenia in 6% of the patients, respectively. Two fatal events (one febrile neutropenia and one sepsis) were reported as being related to study treatment. Conclusions: This phase II trial suggests that cabazitaxel is active as second-line treatment in taxane-pretreated patients with HER2-negative MBC, with manageable toxicity.Keywords
This publication has 16 references indexed in Scilit:
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)Annals of Oncology, 2018
- Preclinical profile of cabazitaxelDrug Design, Development and Therapy, 2014
- Antiproliferative Mechanism of Action of the Novel Taxane Cabazitaxel as Compared with the Parent Compound Docetaxel in MCF7 Breast Cancer CellsMolecular Cancer Therapeutics, 2014
- Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic studyEuropean Journal of Cancer, 2013
- A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II studyEuropean Journal of Cancer, 2011
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 2010
- Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid TumorsClinical Cancer Research, 2009
- A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patientsAnnals of Oncology, 2008
- Impact of chemotherapy beyond the first line in patients with metastatic breast cancerBreast Cancer Research and Treatment, 2007
- Extending Survival with Chemotherapy in Metastatic Breast CancerThe Oncologist, 2005